Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Genotype-guided Treatment in DLBCL
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT05351346
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 66
- Registration Number
- NCT05303792
- Locations
- 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸Marshfield Medical Center - Weston, Weston, Wisconsin, United States
🇺🇸Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 205
- Registration Number
- NCT05304585
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Modified CV Regimen in Optic Pathway Glioma
- Conditions
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Beijing Sanbo Brain Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05278715
- Locations
- 🇨🇳
Capital Medical University Sanbo Brain Hospital, Beijing, China
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 33
- Registration Number
- NCT05270057
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-03-11
- Target Recruit Count
- 36
- Registration Number
- NCT05200312
- Locations
- 🇨🇳
First affiliation hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.